Disease · MONDO_0015667

acute myeloid leukemia by FAB classification

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute myeloid leukemia by FAB classification. Diseases, record MONDO_0015667. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015667

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute myeloid leukemia by FAB classification; Open Targets
Open Targets ID: MONDO_0015667; Open Targets
Other names: AML, NOS, acute myeloid leukaemia NOS, acute myeloid leukaemia not otherwise categorised, acute myeloid leukaemia not otherwise specified, acute myeloid leukemia NOS, acute myeloid leukemia not otherwise categorized, acute myeloid leukemia not otherwise specified, unclassified AML, unclassified acute myeloid leukaemia, unclassified acute myeloid leukemia; Open Targets
NCI Thesaurus: C27753; NCI Thesaurus
Orphanet: ORPHA:167714; Orphanet
Highest stage of its drugs: Approval, for 17 of its 169 drugs, from TTD; Open Targets

Drugs169

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IDARUBICIN	CHEMBL1117	Small molecule	Approval	TTD	4	3	3	Drugs and targets
DAUNORUBICIN	CHEMBL178	Small molecule	Approval	TTD	4	2	2	Drugs and targets
TAGRAXOFUSP	CHEMBL4297573	Protein	Approval	TTD	3	0	0	Drugs and targets
ACLARUBICIN	CHEMBL502620	Small molecule	Approval	TTD	1	0	0	Drugs and targets
APALUTAMIDE	CHEMBL3183409	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DOXECITINE	CHEMBL66115	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ENASIDENIB MESYLATE	CHEMBL3989931	Small molecule	Approval	TTD	1	0	0	Drugs and targets
GEMTUZUMAB OZOGAMICIN	CHEMBL1201506	Antibody drug conjugate	Approval	TTD	1	0	0	Drugs and targets
GILTERITINIB	CHEMBL3301622	Small molecule	Approval	TTD	1	0	0	Drugs and targets
IVOSIDENIB	CHEMBL3989958	Small molecule	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 169

See all 169 drugs

Targets183

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT3	Receptor-type tyrosine-protein kinase FLT3	10	Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	6	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
AURKB	Aurora kinase B	4	Serine/threonine-protein kinase Aurora-B inhibitor	Phase 2	https://conductscience.org/library/genes/9212	Drugs and targets
IDH1	IDH1/IDH2	4	IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor	Approval	https://conductscience.org/library/genes/3417	Drugs and targets
PLK1	Serine/threonine-protein kinase PLK1	4	Serine/threonine-protein kinase PLK1 inhibitor	Phase 3	https://conductscience.org/library/genes/5347	Drugs and targets
CD3D	T cell surface glycoprotein CD3	3	T cell surface glycoprotein CD3 binding agent	Phase 2	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	3	T cell surface glycoprotein CD3 binding agent	Phase 2	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	3	T cell surface glycoprotein CD3 binding agent	Phase 2	https://conductscience.org/library/genes/917	Drugs and targets
IDH2	IDH1/IDH2	3	IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor	Approval	https://conductscience.org/library/genes/3418	Drugs and targets
IL3RA	Interleukin-3 receptor subunit alpha	3	Interleukin-3 receptor subunit alpha binding agent	Approval	https://conductscience.org/library/genes/3563	Drugs and targets

1 to 10 of 183

See all 183 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01721876	Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)	Phase 3	666	2021-11-19	Leukemia, Myeloid, Acute	CYTARABINE, VOLASERTIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00632749	BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment	Phase 2	68	2015-05-25	Leukemia, Myeloid, Acute	BI-811283, CYTARABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00953758	A Study Of PF-04449913 In Select Hematologic Malignancies	Phase 1	47	2024-04-25	Hematologic Malignancies	GLASDEGIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02228525	Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes	Phase 2	25	2022-03-09	Myelodysplastic Syndromes	SELINEXOR	Open Targets' reading of its record	ClinicalTrials.gov
NCT00003436	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia	Phase 3	2,000		Leukemia, Myelodysplastic Syndromes	AMSACRINE, ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, HYDROCORTISONE, METHOTREXATE, MITOXANTRONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00822393	Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)	Phase 3	570		Acute Myeloid Leukemia, Myelodysplastic Syndrome	BUSULFAN, TREOSULFAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00480064	Lomustine and Intermediate Dose Cytarabine in Older Patients With AML	Phase 3	360		Acute Myeloid Leukemia	CYTARABINE, IDARUBICIN, LOMUSTINE, METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04173533	Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT	Phase 3	326		Acute Myeloid Leukemia, Myelodysplasia	AZACITIDINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01617226	Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS	Phase 2	260		Leukemia, Myeloid, Acute	AZACITIDINE, VORINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT04068597	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies	Phase 1/2	250		Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma	AZACITIDINE, BORTEZOMIB, DARATUMUMAB, DEXAMETHASONE, ELRANATAMAB, INOBRODIB, IXAZOMIB, LENALIDOMIDE, POMALIDOMIDE, TECLISTAMAB, VENETOCLAX	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo + Low-dose Cytarabine vs Volasertib + Low-dose Cytarabine: Objective Response (OR)	38 of 222	123 of 444	666	NCT01721876	Trial comparisons
Subjects Assigned to Placebo + Low-dose Cytarabine vs Subjects Assigned to Volasertib + Low-dose Cytarabine: deaths from any cause	40 of 222	138 of 439	661	NCT01721876	Trial comparisons
Subjects Assigned to Placebo + Low-dose Cytarabine vs Subjects Assigned to Volasertib + Low-dose Cytarabine: serious adverse events	163 of 222	380 of 439	661	NCT01721876	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40784355	DERIVED	1	PubMed
34646387	DERIVED	1	PubMed
33993815	DERIVED	1	PubMed
32735836	DERIVED	1	PubMed
31606445	DERIVED	1	PubMed
30450591	DERIVED	1	PubMed
26688487	DERIVED	1	PubMed
24433865	DERIVED	1	PubMed
23763917	DERIVED	1	PubMed
23071272	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015667

GET https://conductscience.org/api/diseases/v1/MONDO_0015667/drugs?page=2

API reference For AI assistants